BGOG-en-9

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Sponsor: Merck Sharp & Dohme Corp.

Participating sites:

  • UZ Leuven, Leuven
  • CHU UCL St-Luc, Bruxelles
  • UZ Antwerpen, Antwerpen
  • AZ Maria Middelares, Gent
  • AZ Delta, Roeselare